Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

The Lancet

Volumn 385, Issue 9972, 2015, Pages 956-965

  Neuschwander Tetri, Brent A ^a   Loomba, Rohit ^b   Sanyal, Arun J ^c   Lavine, Joel E ^d   Van Natta, Mark L ^e   Abdelmalek, Manal F ^f   Chalasani, Naga ^g   Dasarathy, Srinivasan ^k   Diehl, Anna Mae ^f   Hameed, Bilal ⁱ   Kowdley, Kris V ^j   McCullough, Arthur ^h   Terrault, Norah ⁱ   Clark, Jeanne M ^e   Tonascia, James ^e   Brunt, Elizabeth M ^l   Kleiner, David E ^m   Doo, Edward ⁿ  

^a SAINT LOUIS UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f DUKE UNIVERSITY   (United States)

^g INDIANA UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j VIRGINIA MASON MEDICAL CENTER   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

^l WASHINGTON UNIVERSITY   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; OBETICHOLIC ACID; PLACEBO; 6-ETHYLCHENODEOXYCHOLIC ACID; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANGINA PECTORIS; ANOREXIA; APPENDICITIS; ARTICLE; ATAXIA; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYSTITIS; DEHYDRATION; DIARRHEA; DIVERTICULITIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGUS INJURY; FAINTNESS; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEMORRHOID; HUMAN; HUMAN TISSUE; INCONTINENCE; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIVER BIOPSY; LIVER HISTOLOGY; LIVER PAIN; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NEURALGIA; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PAIN; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RESTLESSNESS; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SYSTOLIC BLOOD PRESSURE; TOOTH PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE COLOR; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CHENODEOXYCHOLIC ACID; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84929266699     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61933-4     Document Type: Article

References (30)

1. JA Marrero, RJ Fontana, GI Su, HS Conjeevaram, DM Emick, AS Lok NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States Hepatology 36 2002 1349 1354
2. JM Page, SA Harrison NASH and HCC Clin Liver Dis 13 2009 631 647
3. A Sanyal, A Poklepovic, E Moyneur, V Barghout Population-based risk factors and resource utilization for HCC: US perspective Curr Med Res Opin 26 2010 2183 2191
4. VG Agopian, FM Kaldas, JC Hong et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic Ann Surg 256 2012 624 633
5. K Cusi Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications Gastroenterology 142 2012 711 25.e6
6. R Lomonaco, C Ortiz-Lopez, B Orsak et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease Hepatology 55 2012 1389 1397
7. S Bellentani, R Dalle Grave, A Suppini, G Marchesini Fatty Liver Italian Network Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach Hepatology 47 2008 746 754
8. N Chalasani, Z Younossi, JE Lavine et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 2012 2005 2023
9. G Musso, R Gambino, M Cassader, G Pagano A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease Hepatology 52 2010 79 104
10. V Ratziu Pharmacological agents for NASH Nat Rev Gastroenterol Hepatol 10 2013 676 685
11. H Yau, K Rivera, R Lomonaco, K Cusi The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus Curr Diab Rep 13 2013 329 341
12. G Bjelakovic, D Nikolova, C Gluud Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One 8 2013 e74558
13. M Trauner, T Claudel, P Fickert, T Moustafa, M Wagner Bile acids as regulators of hepatic lipid and glucose metabolism Dig Dis 28 2010 220 224
14. SJ Karpen Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD? Gastroenterology 145 2013 508 510
15. G Porez, J Prawitt, B Gross, B Staels Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease J Lipid Res 53 2012 1723 1737
16. S Modica, RM Gadaleta, A Moschetta Deciphering the nuclear bile acid receptor FXR paradigm Nucl Recept Signal 8 2010 e005
17. AC Calkin, P Tontonoz Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR Nat Rev Mol Cell Biol 13 2012 213 224
18. TQ de Aguiar Vallim, EJ Tarling, PA Edwards Pleiotropic roles of bile acids in metabolism Cell Metab 17 2013 657 669
19. B Cariou The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis Diabetes Metab 34 2008 685 691
20. S Cipriani, A Mencarelli, G Palladino, S Fiorucci FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats J Lipid Res 51 2010 771 784
21. P Fickert, A Fuchsbichler, T Moustafa et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts Am J Pathol 175 2009 2392 2405
22. L Verbeke, R Farre, J Trebicka et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats Hepatology 59 2014 2286 2298
23. S Mudaliar, RR Henry, AJ Sanyal et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 145 2013 574 582
24. KD Lindor, KV Kowdley, EJ Heathcote et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 2004 770 778
25. DE Kleiner, EM Brunt, M Van Natta et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
26. DM Reboussin, DL DeMets, KM Kim, KK Lan Computations for group sequential boundaries using the Lan-DeMets spending function method Control Clin Trials 21 2000 190 207
27. AJ Sanyal, N Chalasani, KV Kowdley et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
28. EM Brunt, DE Kleiner, LA Wilson, P Belt, BA Neuschwander-Tetri for the NASH Clinical Research Network (CRN) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings Hepatology 53 2011 810 820
29. J Hageman, H Herrema, AK Groen, F Kuipers A role of the bile salt receptor FXR in atherosclerosis Arterioscler Thromb Vasc Biol 30 2010 1519 1528
30. KV Kowdley, D Jones, VA Luketic et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC J Hepatol 54 suppl 1 2011 S13